Clinical performance evaluation of the Idylla™ EGFR Mutation Test on formalin-fixed paraffin-embedded tissue of non-small cell lung cance
Hernández, María José
Blanco, Ángela María
de Álava, Enrique
MetadataShow full item record
Background: Detection of epidermal growth factor receptor (EGFR) mutations in exons 18–21 is recommended in all patients with advanced Non-small-cell lung carcinoma due to the demonstrated efficiency of the standard therapy with tyrosine kinase inhibitors in EGFR-mutated patients. Therefore, choosing a suitable technique to test EGFR mutational status is crucial to warrant a valid result in a short turnaround time using the lowest possible amount of tissue material. The Idylla™ EGFR Mutation Test is a simple, fast and reliable method designed for the detection of EGFR mutations from formalin-fixed paraffin-embedded samples. The aim of this study was the Clinical Performace Evaluation of the Idylla™ EGFR Mutation Test on the Idylla™ System. Methods: EGFR mutational status was determined on 132 archived formalin-fixed paraffin-embedded tissue sections with Idylla™ technology. Results were compared with the results previously obtained by routine method in the reference lab (Therascreen® EGFR RGQ PCR v2, Qiagen in Molecular Pathology lab, Hospital Universitario Virgen del Rocío de Sevilla). Results: The overall agreement between results obtained with the Idylla™ EGFR Mutation Test and the Comparator test method was 95.38% (with 1-sided 95% lower limit of 91.7%) showing Positive Diagnostic Agreement of 93.22% and Negative Diagnostic Agreement of 97.18%, with a Limit Of Detection ≤5%. Conclusions: The Idylla™ EGFR Mutation Test passed its clinical validity performance characteristics for accuracy
Is part ofBMC Cancer, 2020, vol. 20
European research projects
The following license files are associated with this item:
Except where otherwise noted, this item's license is described as cc-by (c) Delgado-García et al., 2020
Showing items related by title, author, creator and subject.
Concordance study between one-step nucleic acid amplification and morphologic techniques to detect lymph node metastasis in papillary carcinoma of the thyroid del Carmen, Sofía; Gatius Calderó, Sònia; Franch Arcas, Guzmán; Baena-Fustegueras, Juan A; Gonzalez, Oscar; Zafon, Carles; Cuevas, Dolors; Valls Marsal, Joan; Pérez, Angustias; Martinez, Mercedes; Ros López, Susana; García Macías, Carmen; Iglesias, Carmela; Matias-Guiu, Xavier; de Álava, Enrique (Elsevier, 2016)Tumor resection in papillary thyroid carcinoma (PTC) is often accompanied by lymph node (LN) removal of the central and lateral cervical compartments. One-step nucleic acid amplification (OSNA) is a polymerase chain ...
Proposal for the creation of a national strategy for precision medicine in cancer: a position statement of SEOM, SEAP and SEFH Garrido, Pilar; Aldaz, Azucena; Calleja, Miguel Ángel; Álava, Enrique de; Lamas, María Jesús; Martín, Miguel; Matias-Guiu, Xavier; Palacios, José; Vera, Ruth (Aula Médica Ediciones, 2017)Precision medicine is an emerging approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle for each person. Precision medicine is transforming ...
Sanegre, Sabina; Eritja Sánchez, Núria; De Andrea, Carlos; Diaz-Martin, Juan; Diaz-Lagares, Ángel; Jácome, María Amalia; Salguero-Aranda, Carmen; García Ros, David; Davidson, Ben; Lopez, Rafel; Melero, Ignacio; Navarro, Samuel; Ramon y Cajal, Santiago; Alava, Enrique de; Matias-Guiu, Xavier; Noguera, Rosa (Frontiers Media, 2021)The invasive tumor front (the tumor–host interface) is vitally important in malignant cell progression and metastasis. Tumor cell interactions with resident and infiltrating host cells and with the surrounding extracellular ...